Policy · 2026-06-22
Florida AG Uthmeier Expands 7-OH Emergency Rule to Cover Seven Additional Kratom Derivatives
Source: Florida Office of the Attorney General
Why it matters
Florida's expanded emergency rule — effective immediately upon signing — added mitragynine pseudoindoxyl, 7-acetoxymitragynine, 9-hydroxycorynantheidine, 10-hydroxycorynantheidine, and MGM-15 and MGM-16 to Schedule I, anticipating the chemical workarounds manufacturers used to evade Florida's 2025 rule.
The big picture
Florida first scheduled 7-OH in 2025, and FDACS inspectors subsequently removed over 23,000 illegal packages from retailers across the state. Manufacturers responded by reformulating products using chemically related compounds not covered by the first rule. AG Uthmeier's June 22 action expands the covered compound list to address those substitutions, tightening concentration thresholds and enabling felony-level criminal penalties.
Key findings
- The rule sets a strict limit of no more than 1 milligram of covered compounds per gram (solids) or per milliliter (liquids)
- Any product containing covered compounds must also contain at least 100 times more regular mitragynine by mass, preventing concentrated single-compound formulas
- Florida medical examiners have linked at least 587 overdose deaths to 7-OH and related compounds since 2013
- Poison Control data shows over 25% of recent 7-OH exposure cases required ICU care
- Violations can carry up to 30 years in prison; the rule applies to brands including Hydroxy, 7Tabz, 777 Jackpot Alkaloids, Roxy 7-OH, and 7OHMZ
What they say
AG James Uthmeier stated: "Today I signed an emergency rule because these dangerous concentrated 7-OH products present an imminent hazard to the public safety of Floridians — especially our children and teens. By expanding the rule to include new 7-OH related compounds to Schedule I, we are removing these addictive poisons from store shelves."
Bottom line
Florida's second emergency 7-OH rule closes the compound-substitution loophole that allowed manufacturers to keep selling synthetic kratom derivatives after the 2025 action — and extends Schedule I status to seven related chemicals.